Investor Presentation Q1 2023
35
Novo NordiskⓇ
Investor presentation
First three months of 2023
The unmet need within diabetes care remains large with too few
patients reaching glycaemic target and treated for complications
1 in 2 adults go undiagnosed and more treated patients
should reach their HbA1c target
537m
35m
Prevalence Diagnosed
Treated
Reach target Treated for
complications
Prevalence
Of the 537 million, 36.3 million¹ people are currently treated with
Novo Nordisk diabetes products
6.3 mio treated with GLP-1
4.5 mio treated with
new-generation insulin
12.6 mio treated with
modern insulin
11.5 mio treated with
human insulins
Novo Nordisk products
Source: Diabetes prevalence and diagnosed are based on Diabetes Atlas 10th edition, 2021; Treated is based
on IQVIA patient data; real-world studies indicate between 30-55% of patients reach HbA₁ target <7%.e.g.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388968/
1 In addition to the above-mentioned product classes, oral anti-diabetics constitutes the remainder of people treated with Novo
Nordisk products; Estimated number for full-year 2022 (total available in Novo Nordisk Annual Report 2022)View entire presentation